{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:50:23Z","timestamp":1791521423475,"version":"4.3.4"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Anthracycline-induced cardiotoxicity remains an important complication in patients with breast cancer receiving systemic therapy, and effective preventive strategies remain limited. We conducted a systematic review and meta-analysis to evaluate the cardioprotective effects of beta-blockers in anthracycline-treated breast cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Following PRISMA guidelines, Pubmed, Web of Science, CINAHL, and Cochrane were systematically searched, and the protocol was preregistered on PROSPERO (CRD420261366946). The primary outcome was left ventricular ejection fraction (LVEF), while the secondary outcome was E\/A ratio. Certainty and robustness of the evidence were assessed using GRADE approach and trial sequential analysis (TSA). A meta-analysis was performed using R version 4.6.0, and heterogeneity was assessed using\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      statistics.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 8 studies including 772 patients were analyzed. Beta-blocker therapy was associated with significant preservation of LVEF vs. placebo or standard care (MD, 2.85; 95% CI, 0.58\u20135.12;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      95%). No significant improvement was observed for E\/A ratio (MD, 0.10; 95% CI, \u22120.12 to 0.31;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.25;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      69.7%). However, sensitivity analysis resulted in a statistically significant pooled effect (MD\u2009=\u20090.16, 95% CI: 0.03 to 0.29,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009= 0.01;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200935.9%). TSA showed that the Z-curve crossed the monitoring boundaries favoring beta-blockers for LVEF; however, the required information size (RIS\u2009=\u20091,785) was not reached.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Beta-blockers were associated with preservation of systolic function in anthracycline-treated breast cancer patients. However, no significant benefit was observed for E\/A ratio, and evidence regarding diastolic protection remains inconclusive. Larger, high-quality RCTs are needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>identifier CRD420261366946.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1926758","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:26:18Z","timestamp":1791519978000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of beta-blockers in preventing cardiotoxicity in breast cancer patients receiving anthracyclines: a GRADE-assessed systematic review and meta-analysis with trial sequential analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Victor M.","family":"Samperio","sequence":"first","affiliation":[{"name":"Department of Medicine, Eisenhower Medical Center","place":["Rancho Mirage, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena M.","family":"Murrieta Bruciaga","sequence":"additional","affiliation":[{"name":"Universidad del Valle de M\u00e9xico","place":["Hermosillo, Sonora, M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas Antonio","family":"Casta\u00f1eda Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Universidad de Sonora","place":["Hermosillo, Sonora, M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Coronado Porchas","sequence":"additional","affiliation":[{"name":"Centro de Estudios Universitarios Xochicalco Campus Tijuana","place":["Tijuana, Baja California, M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Chen Liang","sequence":"additional","affiliation":[{"name":"Centro de Estudios Universitarios Xochicalco Campus Tijuana","place":["Tijuana, Baja California, M\u00e9xico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeison","family":"Cruz Castillo","sequence":"additional","affiliation":[{"name":"Universidad Aut\u00f3noma de Santo Domingo","place":["Santo Domingo, Rep\u00fablica Dominicana"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Ghonge","sequence":"additional","affiliation":[{"name":"Department of Medicine, Eisenhower Medical Center","place":["Rancho Mirage, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Saripalli","sequence":"additional","affiliation":[{"name":"Kern Medical Center","place":["Bakersfield, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schulz","sequence":"additional","affiliation":[{"name":"Lucy Curci Cancer Center, Eisenhower Health","place":["Rancho Mirage, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: american society of clinical oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaccao.2024.07.016","article-title":"Anthracycline cardiotoxicity in adult cancer patients: JACC: cardiooncology state-of-the-art review","volume":"6","author":"Camilli","year":"2024","journal-title":"JACC CardioOncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.2147\/CMAR.S166481","article-title":"Nebivolol effect on doxorubicin-induced cardiotoxicity in breast cancer","volume":"10","author":"Cochera","year":"2018","journal-title":"Cancer Manag Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial","volume":"71","author":"Avila","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000442722","article-title":"Carvedilol administration can prevent doxorubicin-induced cardiotoxicity: a double-blind randomized trial","volume":"134","author":"Tashakori Beheshti","year":"2016","journal-title":"Cardiology (Switzerland)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"105116","DOI":"10.1016\/j.esmoop.2025.105116","article-title":"Cardioprotection in patients with anthracycline-treated breast cancer: final analysis from the randomized, placebo-controlled, double-blind SAFE trial","volume":"10","author":"Meattini","year":"2025","journal-title":"ESMO Open"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1016\/j.ijcard.2012.06.023","article-title":"Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study","volume":"167","author":"Kaya","year":"2013","journal-title":"Int J Cardiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.5603\/CJ.a2013.0150","article-title":"Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: a prospective randomized controlled study with six-month follow-up","volume":"21","author":"Elitok","year":"2014","journal-title":"Cardiol J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/FJC.0000000000000470","article-title":"Cardioprotective effects of carvedilol in inhibiting doxorubicin-induced cardiotoxicity","volume":"69","author":"Nabati","year":"2017","journal-title":"J Cardiovasc Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1093\/eurheartj\/ehab843","article-title":"A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer","volume":"43","author":"Lewinter","year":"2022","journal-title":"Eur Heart J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s10741-023-10328-z","article-title":"ACEI\/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis","volume":"28","author":"Gao","year":"2023","journal-title":"Heart Fail Rev"},{"key":"B13","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/BMJ.N71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"B14","year":""},{"key":"B15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"B16","year":""},{"key":"B17","year":""},{"key":"B18","year":""},{"key":"B19","year":""},{"key":"B20","year":""},{"key":"B21","year":""},{"key":"B22","year":""},{"key":"B23","volume-title":"R: The R Project for Statistical Computing","year":"2026"},{"key":"B24","year":""},{"key":"B25","first-page":"302","volume-title":"Basic Theory on Restricted Maximum Likelihood","author":"Montero","year":"2015"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1002\/SIM.7411","article-title":"The Hartung-Knapp modification for random-effects meta-analysis: a useful refinement but are there any residual concerns?","volume":"36","author":"Jackson","year":"2017","journal-title":"Stat Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/SIM.1186;CTYPE:STRING:JOURNAL","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/JRSM.11","article-title":"Outlier and influence diagnostics for meta-analysis","volume":"1","author":"Viechtbauer","year":"2010","journal-title":"Res Synth Methods"},{"key":"B29","volume-title":"Introduction\u2014Meta-Regression Approaches","author":"Morton","year":"2004"},{"key":"B30","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/BIOM.12817","article-title":"Quantifying publication bias in meta-analysis","volume":"74","author":"Lin","year":"2018","journal-title":"Biometrics"},{"key":"B31","year":""},{"key":"B32","doi-asserted-by":"publisher","first-page":"105128","DOI":"10.1016\/j.esmoop.2025.105128","article-title":"Cardiovascular toxicity of breast cancer treatments: from understanding to enhancing survivorship care","volume":"10","author":"Dauccia","year":"2025","journal-title":"ESMO Open"},{"key":"B33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.taap.2004.04.005","article-title":"Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity","volume":"200","author":"Oliveira","year":"2004","journal-title":"Toxicol Appl Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/S40265-015-0435-5","article-title":"A review of nebivolol pharmacology and clinical evidence","volume":"75","author":"Fongemie","year":"2015","journal-title":"Drugs"},{"key":"B35","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1097\/FJC.0000000000001194","article-title":"N-tertaining a new signaling paradigm for the cardiomyocyte \u03b21-adrenergic receptor","volume":"80","author":"Steinberg","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"564","DOI":"10.5114\/aoms\/189501","article-title":"Efficacy and harms associated with beta-blockers for cardiotoxicity in cancer patients undergoing chemotherapy: a systematic review and meta-analysis","volume":"21","author":"Li","year":"2024","journal-title":"Arch Med Sci"},{"key":"B37","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3964","DOI":"10.1002\/cam4.3956","article-title":"Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin","volume":"10","author":"Lee","year":"2021","journal-title":"Cancer Med"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1926758\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:26:19Z","timestamp":1791519979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1926758\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":38,"alternative-id":["10.3389\/fcvm.2026.1926758"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1926758","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"article-number":"1926758"}}